2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
Schiffmann R, Cox TM, Dedieu JF, Gaemers SJM, Hennermann JB, Ida H, Mengel E, Minini P, Mistry P, Musholt PB, Scott D, Sharma J, Peterschmitt MJ. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain 2022, 146: 461-474. PMID: 36256599, PMCID: PMC9924909, DOI: 10.1093/brain/awac379.Peer-Reviewed Original ResearchConceptsGaucher disease type 3Years of treatmentEnzyme replacement therapyWeek 26Biomarker reductionLEAP trialWeek 52Patients 9Neurological manifestationsReplacement therapyPlasma concentrationsType 3Day 1Brain volumeAcid β-glucosidase activityImiglucerase enzyme replacement therapyDiverse neurological manifestationsSystemic disease parametersSerious adverse eventsInfiltrative lung diseaseWhole brain volumeRegional brain activityExploratory endpointsPrimary endpointSecondary endpointsAntibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.Peer-Reviewed Original ResearchAcne vulgarisSevere acne vulgarisAntibiotic resistancePotential side effectsOral tetracyclineGut dysbiosisPatients 9Gastrointestinal upsetRisk of resistanceSide effectsDrug AdministrationTetracycline treatmentSarecyclineTetracycline usageAcneTreatmentTetracyclineAntibiotic resistance riskPathogenic bacteriumRiskVulgarisDizzinessVertigoDysbiosisMinocycline
2013
Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus
Arbelaez AM, Xing D, Cryer PE, Kollman C, Beck RW, Sherr J, Ruedy KJ, Tamborlane WV, Mauras N, Tsalikian E, Wilson DM, White NH, Group F. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatric Diabetes 2013, 15: 127-134. PMID: 23992543, PMCID: PMC3858506, DOI: 10.1111/pedi.12070.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusPeak epinephrineEpinephrine responseDiabetes mellitusT1DM subjectsRecent-onset type 1 diabetes mellitusHypoglycemia-associated autonomic failureBarrier of hypoglycemiaInsulin-induced hypoglycemiaAutonomic failureCounterregulatory hormonesSubsequent hypoglycemiaGlucagon responsePatients 9Recurrent hypoglycemiaGlycemic controlHypoglycemic clampEpinephrine levelsHypoglycemiaHormonal responsesT1DMGlucagonMellitusControl 19CR response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply